Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 15 Pharmaceuticals Companies in India

In this article, we will take a look at the top 15 pharmaceutical companies in India. For more companies, click Top 5 Pharmaceutical Companies in India.

India is the largest producer of generic medications and vaccines worldwide. It makes up about 20% of the entire amount of generic drug supply in the world. With almost 200 nations receiving Indian pharmaceutical exports, India is a significant pharmaceutical exporter.

In addition, India has a strong network of over 10,500 production facilities, over 3,000 pharmaceutical enterprises, and a manpower pool that is highly skilled. Outside of the US, India has the most pharmaceutical manufacturing facilities that adhere to FDA rules.

More than 500 active pharmaceutical ingredients (APIs) are produced in India, supplying 60,000 generic brands. India now has the third-largest API market in the world as a result. Most supplies are made up of over-the-counter medications used to treat common ailments without endangering life. The pharmaceutical industry’s most important cities are Mumbai, Bangalore, Hyderabad, Pune, Visakhapatnam, and Ahmedabad.

One of the top-performing sectors that provide lucrative business prospects is the Indian pharmaceutical market. In recent years, it has experienced enormous expansion. As the Indian pharmaceutical business transitions from a volume maker to a valued supplier in 2022, investors are turning to this sector for safe haven investments. 

In 2020, the pharmaceutical industry’s main focus was on covid medicines, but by 2022, it had turned to other serious ailments, including cancer and anaemia. In addition, research and development were highly valued in the Indian pharmaceutical business. As a result, India emerged as a global medical behemoth’ in 2022 by growing its R&D ecosystem and increasing pharmaceutical exports. 

India’s pharmaceutical sector is presently worth $50 billion. A recent EY FICCI analysis projects that the Indian pharmaceutical industry will expand to $65 billion by 2024 and to $130 billion by 2030 due to a growing consensus over the need to provide patients with novel, innovative remedies. By 2023, it is anticipated that the worldwide market for pharmaceutical products will reach $1 trillion. With this outlook in mind, let’s start our list of top pharmaceuticals company in India.

Our Methodology

This article will examine the biggest pharma companies in India. The companies are listed in ascending order of total employee count because larger enterprises often have a far higher staff count than smaller ones in the same industry.

Top Pharmaceuticals Companies in India

15. Intas Pharmaceuticals Limited

Number of Employees: 8,000 

Intas Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Ahmedabad. It produces generic medications as well as contracts clinical research and production. It operates 18 production sites, 15 of which are in India and the remainder in the United Kingdom and Mexico. Intas has a presence in more than 85 countries and is expanding at a CAGR of over 22%.

14. Emcure Pharmaceuticals

Number of Employees: 9,000

Emcure Pharmaceuticals Limited is a multinational pharmaceutical firm based in Pune, India. Emcure’s product line includes tablets, capsules, and injectables. Emcure Pharmaceuticals’ product portfolio, which has a strong chronic and sub-chronic emphasis, includes all the key medicines and is the industry leader in fields including women’s health, blood-related illnesses, HIV, anti-infectives, cardiac care, and vitamins. Emcure Pharmaceuticals has distribution channels and a network that reaches over 70 countries. In addition, the company has 14 production plants and 5 R&D centers. Emcure Pharmaceuticals Limited generated revenue of $730 million in FY 2022. 

13. Piramal Enterprises Limited (NSE:PEL.NS)

Number of Employees: 13,561

Piramal Enterprises Limited conducts operations in the financial services and pharmaceutical industries in India, North America, Europe, Japan, and other countries. Financial Services and Pharmaceuticals Manufacturing and Services are two of its operating segments. The business provides contract development and manufacturing services, such as drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations, as well as drugs for intrathecal spasticity management, inhalation and injectable anesthesia, injectable pain, antibiotics, and other medications. 

12. Torrent Pharmaceuticals Limited (NSE:TORNTPHARM.NS)

Number of Employees: 13,900

Torrent Pharmaceuticals Limited is the main company of the Torrent Group and is one of the leading Pharma companies in India. The firm is among the leaders in the therapeutic area of cardiovascular, central nervous system, gastrointestinal, and women’s healthcare. Torrent Pharmaceuticals Limited in India originally introduced the idea of specialty marketing. The company is also well-represented in cancer, anti-infectives, diabetology, and pain treatment categories. Additionally, Torrent Pharma has a significant global footprint that spans 40 nations, with activities in developed and rising areas such as the US, Europe, Brazil, and the rest of the globe. The company operates through its 12 fully-owned subsidiaries, having a presence in 40 countries. In 2022, the company’s revenue was $1.1 billion.

11. Abbott India Limited (NSE:ABBOTINDIA.NS)

Number of Employees: 14,000

Abbott India Limited, located in Mumbai, is a publicly traded corporation and a subsidiary of Abbott Capital India Limited. It has one of the quickest rates of growth among Indian pharmaceutical businesses. The business offers trustworthy, high-quality drugs in various therapeutic areas, such as women’s health, gastroenterology, cardiology, metabolic disorders, central nervous system, pain management, pre-term labor, vitamins, sleeplessness, vaccinations, consumer health, etc. Thyronorm, Eptoin, Duphaston, Duphalac, Vertin, Udiliv, Heptral, Digene, Cremaffin, and Prothiaden are some of its well-known trademarks.

10. Biocon Limited (NSE:BIOCON.NS)

Number of Employees: 14,750

Biocon Limited (NSE:BIOCON.NS) makes drugs, therapeutic compounds, and herbal items. Generics, Novel Biologics, Biosimilars, and Research Services are among the company’s segments. Its primary focus areas include diabetes, cancer, immunology, ophthalmology, and bone health issues. It also offers comprehensive services for the research, development, and manufacture of both small and large molecules. The company provides customer assistance in around 120 countries, including Europe and the US. INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab), and KRABEVA (Bevacizumab) are some of Biocon’s most important brands in India. The company’s consolidated revenue grew 14% to $1.1 billion in FY22.

9. Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS)

Number of Employees: 15,415

Glenmark Pharmaceuticals Limited develops, produces, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and globally through its subsidiaries. In the therapeutic fields of dermatology, respiratory, and cancer, the firm offers both branded and generic formulations and different active pharmaceutical components. The company operates 14 production plants in Argentina, the Czech Republic, India, and the US. Numerous regulatory agencies inspect these facilities, such as the US-FDA, MHRA UK, and ANVISA Brazil. In addition, being a research-driven company, Glenmark Pharmaceuticals Limited has also made investments in special R&D facilities for international markets. Glenmark Pharmaceuticals Limited brought in $1.48 billion in sales in FY 2022.

8. Alkem Laboratories Ltd. (NSE:ALKEM.NS)

Number of Employees: 17,000

Alkem Laboratories is a pharmaceutical company with international operations. The business creates, produces, and markets pharmaceutical and nutraceutical goods. It has built a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutritional areas, as well as acute treatment. Branded Generics, Generic Drugs, API Nutraceuticals, and Biosimilars are among the company’s product offerings. As of March 31, 2022, Alkem had 21 production facilities—19 in India and 2 in the US. Clavam, Pan 40, Taxim-O, Taxim-D, Taxim Injection, Gemcal, A to Z Tabs, Ondem, Xone, Sumo, Zocef, Pipzo, Swich, Xone XP, and Uprise D3 are some of its top brands.

7. Divi’s Laboratories (NSE:DIVISLAB:NS)

Number of Employees: 17000

Established in 1990, Divi’s Laboratories is a top producer of active pharmaceutical ingredients, exporting top-notch goods to over 95 nations. Europe accounts for most of the company’s sales, followed by North America, India, and Asia. The business views investing in mergers and acquisitions as a possible part of its operational growth plan to boost its R&D, production, and marketing capabilities. In FY22, Divi’s Laboratories generated $1.1 billion in revenue.

6. Lupin Limited (NSE:LUPIN.NS)

Number of Employees: 20,000

Lupin Limited develops, produces, distributes, and markets a wide range of biotechnology products, branded and generic formulations, and active pharmaceutical ingredients (APIs). Cardiovascular, asthma, diabetes management, pediatrics, central nervous system, gastroenterology, anti-infectives, nonsteroidal anti-inflammatory medications (NSAIDs), anti-TB, and cephalosporins are among its areas of specialization. With 18 production facilities, Lupin sells its goods in more than 100 nations. India, the US, Japan, Europe, South Africa, the Philippines, and Australia are key markets for the company. The Indian pharmaceutical firm Lupin Limited announced net revenues of $1.96 billion for the fiscal year 2022.

Click to continue reading and see Top 5 Pharmaceuticals Company in India.

Suggested articles:

Disclosure: None. Top 15 Pharmaceuticals Company in India is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

  • The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
  • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
  • Lifetime Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

  1. Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
  2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
  3. Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…